COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
1 . A pharmaceutical composition comprising an inhibitory means for inhibiting JAK in a subject and a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means is a pyrimidine diamine means.
3 . The pharmaceutical composition according to claim 2 , wherein the pyrimidine diamine means is a 5-halogenpyrimidine diamine means or a 5-alkylpyrimidine diamine means.
4 . The pharmaceutical composition according to claim 2 , wherein the pyrimidine diamine means is a 5-fluoropyrimidine diamine means or a 5-methylpyrimidine diamine means.
5 . The pharmaceutical composition according to claim 2 , wherein the pyrimidine diamine means is a 2,4-diaminopyrimidine means.
6 . The pharmaceutical composition according to claim 5 , wherein the 2,4-diaminopyrimidine means comprises a C 6-10 aryl or a 5-10 membered heteroaryl on the 2-amino moiety.
7 . The pharmaceutical composition according to claim 6 , wherein the C 6-10 aryl or 5-10 membered heteroaryl is a bicyclic ring moiety.
8 . The pharmaceutical composition according to claim 6 , wherein the C 6-10 aryl or 5-10 membered heteroaryl is an optionally substituted phenyl, optionally substituted pyridinyl, or optionally substituted isoindolinyl moiety.
9 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means is an aminobenzoxazolone means.
10 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means is an (aminopyrimidin-4-yl)amino)benzo [d]oxazol-2(3H)-one means.
11 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means is a salt.
12 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means comprises a pyrimidinediamine moiety, a benzoxazolone moiety and a phenyl moiety.
13 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means comprises a pyrimidinediamine moiety, a benzoxazolone moiety and a pyridinyl moiety.
14 . The pharmaceutical composition according to claim 1 , wherein the inhibitory means comprises a pyrimidinediamine moiety, a benzoxazolone moiety and a bicyclic ring moiety.
15 . The pharmaceutical composition according to claim 14 , wherein the bicyclic ring moiety comprises a phenyl ring and a 5-membered partially saturated ring optionally comprising one or more heteroatoms.
16 . A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with an amount of an inhibitory means for inhibiting the JAK kinase, the amount being effective to inhibit an activity of the JAK kinase.
17 . A method, comprising administering to a subject a pyrimidine diamine means for inhibiting a JAK kinase.
18 . A method of treating a JAK kinase-mediated disease, comprising administering to a subject an amount of the pharmaceutical composition of claim 1 effective to treat or prevent the JAK kinase-mediated disease.
19 . A method of treating a T-cell mediated autoimmune disease, comprising administering to a patient suffering from such an autoimmune disease an amount of the pharmaceutical composition of claim 1 effective to treat the autoimmune disease.
20 . A method of treating a disease and/or disorder of the eye, comprising administering to a subject an amount of the pharmaceutical composition of claim 1 effective to treat the disease and/or disorder of the eye.